Track Open Orphan plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Open Orphan plc CRO.F · Stock Open Open Orphan plc in new tab

0.0645 EUR
EPS
-0.01
P/B
1.21
ROE
-14.47
Beta
1.69
Loading chart...
Key Metrics
EPS-0.01
Book Value0.06
Price to Book1.21
Debt/Equity38.75
% Insiders3.164%
Growth
Revenue Growth-0.17%

DCF Valuation

Tweak assumptions to recompute fair value for Open Orphan plc (CRO.F)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Open Orphan plc Logo Open Orphan plc Analysis (CRO.F)

United Kingdom Health Care Official Website Stock

Is Open Orphan plc a good investment? Open Orphan plc (CRO.F) is currently trading at 0.0645 EUR.

Investor FAQ

Does Open Orphan plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is Open Orphan plc?

Open Orphan plc is classified as a Stock. You can compare it against 7 other assets in the "Related Symbols" list on this page.

Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD. In addition, the company offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, it provides pre­clinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company offers services to big pharma and biotech organizations. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

Exchange Ticker
ASX (Australia) CRO.AX
PNK (United States) OPORF
LSE (United Kingdom) ORPH.L
HVO.L
FRA (Germany) CRO.F
BER (Germany) CRO.BE
MUN (Germany) CRO.MU
Trades
Dividend History paid per year (EUR)
Historical Dividends
Year Total Dividends
2025
0.00 EUR
May 15, 2025 0.0023
2024
0.00 EUR
April 18, 2024 0.0023
2023
0.01 EUR
May 4, 2023 0.0052
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion